Evidence map›Paper›PMID 24942865›Full record

ArticleCarcinogenesis2014

Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.

Quanri Jin, Hyo-Jong Lee, Hye-Young Min, John Kendal Smith, Su Jung Hwang, Young Mi Whang, Woo-Young Kim, Yeul Hong Kim, Ho-Young Lee

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Quanri JinDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Hyo-Jong LeeCollege of Pharmacy, Inje University, Gimhae, Gyungnam 621-749, Republic of Korea.
Hye-Young MinCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea.
John Kendal SmithDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Su Jung HwangCollege of Pharmacy, Inje University, Gimhae, Gyungnam 621-749, Republic of Korea.
Young Mi WhangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Woo-Young KimDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA, Research Center for Cell Fate Control, College of Pharmacy, Sookmyung Women's University, Seoul 140-745, Republic of Korea and.
Yeul Hong KimDepartment of Internal Medicine, Korea University College of Medicine, Seoul 136-705, Republic of Korea.
Ho-Young LeeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea, hylee135@snu.ac.kr.
The University of Texas MD Anderson Cancer Center · USInje University · KRKorea University · KRSeoul National University · KRSookmyung Women's University · KR

Funding

Novel Strategy for Lung Cancer Treatment using IGFBP-3R01CA100816 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LEE, HO-YOUNG · 2004 to 2013
$2.0M
NCI NIH HHS R01 CA100816
6 · The paper itself

Abstract

Insulin-like growth factor (IGF)-dependent and -independent antitumor activities of insulin-like growth factor binding protein-3 (IGFBP-3) have been proposed in human non-small cell lung cancer (NSCLC) cells. However, the mechanism underlying regulation of IGFBP-3 expression in NSCLC cells is not well understood. In this study, we show that activation of Akt, especially Akt3, plays a major role in the mRNA expression and protein stability of IGFBP-3 and thus antitumor activities of IGFBP-3 in NSCLC cells. When Akt was activated by genomic or pharmacologic approaches, IGFBP-3 transcription and protein stability were decreased. Conversely, suppression of Akt increased IGFBP-3 mRNA levels and protein stability in NSCLC cell lines. Characterization of the effects of constitutively active form of each Akt subtype (HA-Akt-DD) on IGFBP-3 expression in NSCLC cells and a xenograft model indicated that Akt3 plays a major role in the Akt-mediated regulation of IGFBP-3 expression and thus suppression of Akt effectively enhances the antitumor activities of IGFBP-3 in NSCLC cells with Akt3 overactivation. Collectively, these data suggest a novel function of Akt3 as a negative regulator of IGFBP-3, indicating the possible benefit of a combined inhibition of IGFBP-3 and Akt3 for the treatment of patients with NSCLC.

Indexed as

AnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell NucleusChromonesHumansInsulin-Like Growth Factor Binding Protein 3Lung NeoplasmsMiceMice, NudeMorpholinesPhosphoinositide-3 Kinase InhibitorsProtein StabilityProto-Oncogene Proteins c-aktTranscription, GeneticXenograft Model Antitumor Assays2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-oneAKT3 protein, humanChromonesIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 3MorpholinesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-akt

Identifiers

PMID24942865
PMCPMC4178467
OpenAlexW2155894245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.